ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Denali Announces Fast Track Designation to DNL310 for Hunter Syndrome
March 18, 2021Denali Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II). -
Biogen and Denali sign Parkinson’s drug deal worth $2bn
August 10, 2020Biogen has entered a binding agreement with Denali Therapeutics to jointly develop and commercialise therapeutics for Parkinson’s disease. -
Ex-Genentech Employees' Denali Breaks 2017 IPO Records, Raises $250M
December 11, 2017Denali Therapeutics, launched in May 2015 by three former Genentech researchers, just went public, raising $250 million with shares priced at $18. It is trading under the ticker DNLI.
Pharma Sources Insight January 2025
